Article

VEGF drug improves vision in patients with wet AMD

Based on a planned, interim analysis of a phase II randomized study, Regeneron Pharmaceuticals and Bayer HealthCare said patients with wet age-related macular degeneration (AMD) who received just one dose of their vascular endothelial growth factor (VEGF) drug (Trap-Eye) maintained or improved vision at 12 weeks.

Key Points

Tarrytown, NY-Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said patients with wet age-related macular degeneration who received just one dose of their vascular endothelial growth factor (VEGF) drug (Trap-Eye) had maintained or improved vision at 12 weeks.

In a planned, interim analysis of a phase II randomized study, the companies found the compound achieved a statistically significant reduction in retinal thickness after 12 weeks compared with baseline. Mean change from baseline in visual acuity also demonstrated statistically significant improvement.

Even patients who received a single dose, on average, saw a decrease in excess retinal thickness. Treatment with the drug was generally well-tolerated, and no serious adverse events were reported.

Based on these results, the companies plan to initiate phase III trials in the second half of this year.

The compound is a human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related placental growth factor. It blocks these growth factors to prevent abnormal angiogenesis.

The companies will commercialize the drug jointly outside the United States, and Regeneron will maintain exclusive rights in the United States.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times)  ASCRS 2025: Joaquin De Rojas, MD, leverages machine learning model to predict arcuate outcomes
(Image credit: Ophthalmology Times) ASCRS 2025: AnnMarie Hipsley, DPT, PhD, presents VESA for biomechanical simulation of presbyopia progression
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
© 2025 MJH Life Sciences

All rights reserved.